Jigsaw Medical

jigsawmedical.com

Founded in 2012 by Chris Percival, Jigsaw Medical has quickly become one of the UK leaders in medical services, offering a range of services for the commercial, media, events sectors and the NHS. Jigsaw Medical is divided into three clear entities; our Clinical Services Division, Training Division, and our Specialist Projects Division. We are committed to delivering clinically focused and harmonised solutions to both NHS and private clients. Our Clinical Services Division specialises in providing ambulance services, event medical cover, and TV / Film unit medics whilst our Training Division provides first aid training courses and clinical education. Finally, our Special Projects Division provides specific medical training and medical staff for close protection, hostile, and remote environments – making up our four clear divisions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

HEALTHMYNE'S RADIOMIC TECHNOLOGY LEVERAGED TO IDENTIFY BIOMARKERS THAT PREDICT IMMUNOTHERAPY TREATMENT RESPONSES

HealthMyne | September 22, 2021

news image

HealthMyne, a pioneer in applied radiomics, announced that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy. In the Cancers article, researchers led by Vincenza Granata evaluated HealthMyne's technology as a quantitative imaging decision support tool for radiomic analysis of lung adenocarcinoma i...

Read More

MEDICAL

ALTERITY THERAPEUTICS LAUNCHES ATH434 PHASE 2 CLINICAL TRIAL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SYSTEM ATROPHY

Alterity Therapeutics | June 03, 2022

news image

Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand. MSA is a rare neurodegenerative disease. While it is similar to Parkinson's disease, MSA progresses m...

Read More

TRANSPOSABLE ELEMENTS ROLE IN GENETIC EXPRESSION COULD IMPROVE STUDY OF NEURODEGENERATIVE DISEASE

GEN | April 15, 2020

news image

Researchers in Michigan published a study “Transposable elements contribute to cell and species-specific chromatin looping and gene regulation in mammalian genomes” in Nature Communications that shows that transposable elements play an important role in regulating genetic expression with implications to advance the understanding of genetic evolution, with potential applications in neurodegenerative diseases. Transposable elements move around the cell, and, unlike previously thought, ...

Read More

MEDTECH

SOLVIAS ACQUIRES CERGENTIS TO BOLSTER BIOLOGICS AND CELL & GENE THERAPY CAPABILITIES

Solvias | July 18, 2022

news image

Solvias, one of the world's leading independent pharmaceutical testing and manufacturing companies, announced today that it has acquired Utrecht, Netherlands-based Cergentis. The acquisition bolsters Solvias' platform of biologics and cell and gene therapy testing solutions. According to pharmaceutical market intelligence provider, Evaluate, global sales of cell and gene therapies are projected to accelerate at a 63% compound annual growth rate through 2026. As more resear...

Read More
news image

MEDICAL

HEALTHMYNE'S RADIOMIC TECHNOLOGY LEVERAGED TO IDENTIFY BIOMARKERS THAT PREDICT IMMUNOTHERAPY TREATMENT RESPONSES

HealthMyne | September 22, 2021

HealthMyne, a pioneer in applied radiomics, announced that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy. In the Cancers article, researchers led by Vincenza Granata evaluated HealthMyne's technology as a quantitative imaging decision support tool for radiomic analysis of lung adenocarcinoma i...

Read More
news image

MEDICAL

ALTERITY THERAPEUTICS LAUNCHES ATH434 PHASE 2 CLINICAL TRIAL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SYSTEM ATROPHY

Alterity Therapeutics | June 03, 2022

Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand. MSA is a rare neurodegenerative disease. While it is similar to Parkinson's disease, MSA progresses m...

Read More
news image

TRANSPOSABLE ELEMENTS ROLE IN GENETIC EXPRESSION COULD IMPROVE STUDY OF NEURODEGENERATIVE DISEASE

GEN | April 15, 2020

Researchers in Michigan published a study “Transposable elements contribute to cell and species-specific chromatin looping and gene regulation in mammalian genomes” in Nature Communications that shows that transposable elements play an important role in regulating genetic expression with implications to advance the understanding of genetic evolution, with potential applications in neurodegenerative diseases. Transposable elements move around the cell, and, unlike previously thought, ...

Read More
news image

MEDTECH

SOLVIAS ACQUIRES CERGENTIS TO BOLSTER BIOLOGICS AND CELL & GENE THERAPY CAPABILITIES

Solvias | July 18, 2022

Solvias, one of the world's leading independent pharmaceutical testing and manufacturing companies, announced today that it has acquired Utrecht, Netherlands-based Cergentis. The acquisition bolsters Solvias' platform of biologics and cell and gene therapy testing solutions. According to pharmaceutical market intelligence provider, Evaluate, global sales of cell and gene therapies are projected to accelerate at a 63% compound annual growth rate through 2026. As more resear...

Read More

Resources

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Connecting materials sciences with fungal biology: a sea of possibilities

Whitepaper

resource image

RESEARCH

BIOTECHNOLOGY UPDATE

Whitepaper

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Risk assessment of fungal materials

Whitepaper

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Connecting materials sciences with fungal biology: a sea of possibilities

Whitepaper

resource image

RESEARCH

BIOTECHNOLOGY UPDATE

Whitepaper

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Risk assessment of fungal materials

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us